Literature DB >> 15678092

Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.

Ann Maria K Hansen1, John Bondo Hansen, Richard D Carr, Frances M Ashcroft, Philip Wahl.   

Abstract

1. The beta-cell K(ATP) channel is composed of two types of subunit - the inward rectifier K(+) channel (Kir6.2) which forms the channel pore, and the sulphonylurea receptor (SUR1), which serves as a regulatory subunit. The N-terminus of Kir6.2 is involved in transduction of sulphonylurea binding into channel closure, and deletion of the N-terminus (Kir6.2DeltaN14) results in functional uncoupling of the two subunits. In this study, we investigate the interaction of the hypoglycaemic agents repaglinide and glibenclamide with SUR1 and the effect of Kir6.2 on this interaction. We further explore how the binding properties of repaglinide and glibenclamide are affected by functional uncoupling of SUR1 and Kir6.2 in Kir6.2DeltaN14/SUR1 channels. All binding experiments are performed on membranes in ATP-free buffer at 37 degrees C. 2. Repaglinide was found to bind with low affinity (K(D)=59+/-16 nM) to SUR1 alone, but with high affinity (increased approximately 150-fold) when SUR1 was co-expressed with Kir6.2 (K(D)=0.42+/-0.03 nM). Glibenclamide, tolbutamide and nateglinide all bound with marginally lower affinity to SUR1 than to Kir6.2/SUR1. 3. Repaglinide bound with low affinity (K(D)=51+/-23 nM) to SUR1 co-expressed with Kir6.2DeltaN14. In contrast, the affinity for glibenclamide, tolbutamide and nateglinide was only mildly changed as compared to wild-type channels. 4. In whole-cell patch-clamp experiments inhibition of Kir6.2DeltaN14/SUR1 currents by both repaglinide and nateglinde is abolished. 5. The results suggest that Kir6.2 causes a conformational change in SUR1 required for high-affinity repaglinide binding, or that the high-affinity repaglinide-binding site includes contributions from both SUR1 and Kir6.2. Glibenclamide, tolbutamide and nateglinide binding appear to involve only SUR1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15678092      PMCID: PMC1576033          DOI: 10.1038/sj.bjp.0706082

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

Review 1.  Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.

Authors:  V Ambavane; R Patil; S S Ainapure
Journal:  J Postgrad Med       Date:  2002 Jul-Sep       Impact factor: 1.476

2.  Regulation by sulfanylurea receptor type 1 of a non-selective cation channel involved in cytotoxic edema of reactive astrocytes.

Authors:  J Marc Simard; Mingkui Chen
Journal:  J Neurosurg Anesthesiol       Date:  2004-01       Impact factor: 3.956

3.  Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.

Authors:  M Dabrowski; P Wahl; W E Holmes; F M Ashcroft
Journal:  Diabetologia       Date:  2001-06       Impact factor: 10.122

4.  Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.

Authors:  S Hu; S Wang; B Fanelli; P A Bell; B E Dunning; S Geisse; R Schmitz; B R Boettcher
Journal:  J Pharmacol Exp Ther       Date:  2000-05       Impact factor: 4.030

5.  Molecular structure of the glibenclamide binding site of the beta-cell K(ATP) channel.

Authors:  M V Mikhailov; E A Mikhailova; S J Ashcroft
Journal:  FEBS Lett       Date:  2001-06-15       Impact factor: 4.124

6.  Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1.

Authors:  Takashi Miki; Masashi Suzuki; Tadao Shibasaki; Hiroko Uemura; Toshiaki Sato; Kaori Yamaguchi; Haruhiko Koseki; Toshihiko Iwanaga; Haruaki Nakaya; Susuma Seino
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

7.  The tolbutamide site of SUR1 and a mechanism for its functional coupling to K(ATP) channel closure.

Authors:  A P Babenko; G Gonzalez; J Bryan
Journal:  FEBS Lett       Date:  1999-10-15       Impact factor: 4.124

8.  Physiological and pathophysiological roles of ATP-sensitive K+ channels.

Authors:  Susumu Seino; Takashi Miki
Journal:  Prog Biophys Mol Biol       Date:  2003-02       Impact factor: 3.667

9.  SUR-dependent modulation of KATP channels by an N-terminal KIR6.2 peptide. Defining intersubunit gating interactions.

Authors:  Andrey P Babenko; Joseph Bryan
Journal:  J Biol Chem       Date:  2002-09-03       Impact factor: 5.157

10.  Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.

Authors:  Ann Maria K Hansen; Inge T Christensen; John Bondo Hansen; Richard D Carr; Frances M Ashcroft; Philip Wahl
Journal:  Diabetes       Date:  2002-09       Impact factor: 9.461

View more
  11 in total

1.  Incomplete dissociation of glibenclamide from wild-type and mutant pancreatic K ATP channels limits their recovery from inhibition.

Authors:  U Russ; P Kühner; R Prager; D Stephan; J Bryan; U Quast
Journal:  Br J Pharmacol       Date:  2009-01-13       Impact factor: 8.739

2.  The mutation Y1206S increases the affinity of the sulphonylurea receptor SUR2A for glibenclamide and enhances the effects of coexpression with Kir6.2.

Authors:  Damian Stephan; Eva Stauss; Ulf Lange; Holger Felsch; Cornelia Löffler-Walz; Annette Hambrock; Ulrich Russ; Ulrich Quast
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

3.  ATP binding without hydrolysis switches sulfonylurea receptor 1 (SUR1) to outward-facing conformations that activate KATP channels.

Authors:  Jelena Sikimic; Timothy S McMillen; Cita Bleile; Frank Dastvan; Ulrich Quast; Peter Krippeit-Drews; Gisela Drews; Joseph Bryan
Journal:  J Biol Chem       Date:  2018-12-26       Impact factor: 5.157

4.  Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel.

Authors:  Petra Kühner; Renate Prager; Damian Stephan; Ulrich Russ; Marcus Winkler; David Ortiz; Joseph Bryan; Ulrich Quast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-15       Impact factor: 3.000

Review 5.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

6.  Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.

Authors:  D Stephan; M Winkler; P Kühner; U Russ; U Quast
Journal:  Diabetologia       Date:  2006-07-25       Impact factor: 10.122

Review 7.  Kir6.1 and SUR2B in Cantú syndrome.

Authors:  Conor McClenaghan; Colin G Nichols
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-25       Impact factor: 5.282

Review 8.  Review. SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator.

Authors:  Jussi Aittoniemi; Constantina Fotinou; Tim J Craig; Heidi de Wet; Peter Proks; Frances M Ashcroft
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-01-27       Impact factor: 6.237

9.  Analysis of two KCNJ11 neonatal diabetes mutations, V59G and V59A, and the analogous KCNJ8 I60G substitution: differences between the channel subtypes formed with SUR1.

Authors:  Marcus Winkler; Rebekka Lutz; Ulrich Russ; Ulrich Quast; Joseph Bryan
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

10.  Sulfonylureas suppress the stimulatory action of Mg-nucleotides on Kir6.2/SUR1 but not Kir6.2/SUR2A KATP channels: a mechanistic study.

Authors:  Peter Proks; Heidi de Wet; Frances M Ashcroft
Journal:  J Gen Physiol       Date:  2014-11       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.